UY39807A - VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE A - Google Patents
VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE AInfo
- Publication number
- UY39807A UY39807A UY0001039807A UY39807A UY39807A UY 39807 A UY39807 A UY 39807A UY 0001039807 A UY0001039807 A UY 0001039807A UY 39807 A UY39807 A UY 39807A UY 39807 A UY39807 A UY 39807A
- Authority
- UY
- Uruguay
- Prior art keywords
- variants
- genomodified
- nrg
- erbb4
- improved selectivity
- Prior art date
Links
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 title 1
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 title 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 abstract 1
- 102000044591 ErbB-4 Receptor Human genes 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 1
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a variantes de la neurregulina-1 genomodificadas que activan selectivamente los receptores ErbB4 pero no activan los receptores ErbB3. La invención también proporciona métodos de uso de dichas variantes para tratar la insuficiencia cardíaca.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163209248P | 2021-06-10 | 2021-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39807A true UY39807A (es) | 2022-12-30 |
Family
ID=82492400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039807A UY39807A (es) | 2021-06-10 | 2022-06-09 | VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE A |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220402985A1 (es) |
EP (1) | EP4351722A1 (es) |
JP (1) | JP2024522579A (es) |
AR (1) | AR126114A1 (es) |
AU (1) | AU2022289721A1 (es) |
CA (1) | CA3222782A1 (es) |
MX (1) | MX2023014680A (es) |
TW (1) | TW202306975A (es) |
UY (1) | UY39807A (es) |
WO (1) | WO2022261299A1 (es) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716A (en) | 1848-08-15 | Valve of water-iiams | ||
US930A (en) | 1838-09-19 | Jordan l | ||
US1104741A (en) * | 1913-08-16 | 1914-07-21 | Nashua Card Gummed & Coated Paper Company | Paper-feeder. |
US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US5607342A (en) * | 1995-03-27 | 1997-03-04 | Demeton Usa, Inc. | High velocity flame jet apparatus for thermoabrasive cutting or cleaning or for the application of protective coatings |
US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
ATE275628T1 (de) | 1996-01-11 | 2004-09-15 | Immunex Corp | Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
EP0970207B1 (en) * | 1997-02-10 | 2009-04-01 | Genentech, Inc. | Heregulin variants |
US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
CA2580107A1 (en) | 2004-09-13 | 2006-03-23 | University Of Southampton | Growth factor treatment for asthma |
AU2005289685B2 (en) | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
US20110054851A1 (en) | 2007-07-06 | 2011-03-03 | Markus Heller | Method for detecting information relevant for the characterization of joint movements |
US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
US8609620B2 (en) * | 2008-11-28 | 2013-12-17 | Zensun (Shanghai) Science & Technology Ltd. | Neuregulin peptides and their use |
-
2022
- 2022-06-09 MX MX2023014680A patent/MX2023014680A/es unknown
- 2022-06-09 TW TW111121403A patent/TW202306975A/zh unknown
- 2022-06-09 AR ARP220101527A patent/AR126114A1/es unknown
- 2022-06-09 EP EP22741092.5A patent/EP4351722A1/en active Pending
- 2022-06-09 UY UY0001039807A patent/UY39807A/es unknown
- 2022-06-09 AU AU2022289721A patent/AU2022289721A1/en active Pending
- 2022-06-09 US US17/836,425 patent/US20220402985A1/en active Pending
- 2022-06-09 WO PCT/US2022/032801 patent/WO2022261299A1/en active Application Filing
- 2022-06-09 JP JP2023575412A patent/JP2024522579A/ja active Pending
- 2022-06-09 CA CA3222782A patent/CA3222782A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220402985A1 (en) | 2022-12-22 |
WO2022261299A1 (en) | 2022-12-15 |
CA3222782A1 (en) | 2022-12-15 |
TW202306975A (zh) | 2023-02-16 |
EP4351722A1 (en) | 2024-04-17 |
AR126114A1 (es) | 2023-09-13 |
AU2022289721A1 (en) | 2024-01-04 |
JP2024522579A (ja) | 2024-06-21 |
MX2023014680A (es) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
DOP2021000130A (es) | Moduladores de la expresion de hsd17b13 | |
BR112018075039A2 (pt) | métodos de tratamento da síndrome de prader-willi | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
BR112022017192A2 (pt) | Variantes de transglutaminase | |
ECSP22012650A (es) | Composiciones que comprenden tigolaner para el control de parásitos | |
CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
CO2021000087A2 (es) | Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x | |
CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
UY39807A (es) | VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE A | |
CL2022000807A1 (es) | Compuesto bicíclico y uso del mismo | |
CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
CL2019001618A1 (es) | Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. | |
CO2023018652A2 (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos | |
CO2021005579A2 (es) | Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3 | |
CL2020002347A1 (es) | Nuevo compuesto y composición farmacéutica que lo comprende | |
CL2020002128A1 (es) | Composición herbicida que comprende por lo menos un compuesto activo fenólico | |
BR102020023578A8 (pt) | Composições e métodos para tratamento do olho | |
BR112022012436A2 (pt) | Formulação compósita e método para preparar a formulação compósita | |
CL2019000471A1 (es) | Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448) | |
CL2023001137A1 (es) | Procedimiento para la purificación de pleuromutilinas |